icon corporate overview
TRANSCRIPT
ICON Company Overview
What we doICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.
We specialise in the strategic development, management and analysis of programs that support Clinical Development ‐ from
compound selection to Phase I‐IV clinical studies
ICON’s mission is to help accelerate the development of drugs that save lives and improve the quality of life.
ICON’s vision is to be the CRO partner of choice by delivering
best in class information, solutions, and performance.
ICON The Journey So Far
The Journey so Far ….
The Journey So Far
1990 2014
$0.5m $1.5bn
5 Staff 11,200 Staff
Global Scale
11,200 Employees
4,300 + Europe,Middle East, Africa
PHD or Higher - 9%Master Degree - 24%Bachelor Degree - 39%Diploma/Certificate - 13%Other - 15%
2,000 + Asia Pacific
4,900 +The Americas
• Strong global presence and growing in emerging markets
GlobalScale
• Experienced management team
• Highly educated and qualified staff
• Therapeutically aligned expertise
• Medical and Scientific networks
• Thought leadership through ICON Consulting
Depth of Talent
• Industry leading partnership models
• Leader in outcomes research and real world evidence
• Global site and patient networks
• Differentiated technology and analytics
• Global business model leveraging support costs
Competitively Positioned
A Market Leader Positioned for Continued Growth
Full Service Portfolio : Early Phase to Commercialisation
Brendan Brennan
CFO (M&A, IR)
Executive Leadership
Ciaran Murray
CEO ICON Plc.
Diarmaid Cunningham
General Counsel
Don KraftEVP HR
Steve CutlerCOO, ICON Plc.
Brendan Buckley
Chief Medical Officer
Tom O’Leary CIO
Neil McCulloughEVP Quality &
Training
Journey to Trusted Partner
ICON Strategic Pillars
Build Scale
Improve Competitiveness
Leadership & Talent
Leverage Informatics
Market Relevant Expertise
Strategy
Building Scale: Organic growth and targeted M&A
Backlog Growth
Footprint ExpansionTargeted M &A
Revenue Growth
Backlog $bn
Improving Competitiveness
Flat efficient structure
Operating Margin Improvement
Global Business Model – leveraging SG&A
% SGA
Leadership and Talent
Attracting Talent: ICON/UCD Graduate Certificate in Clinical Research
Career Frameworks
Staff Development
Overall reduction in staff turnover
Leveraging Informatics
• Risk Based Monitoring• Safety Signals• Labs Data
• Increasing Firecrest Adoption
• ICON Chair of Data Analytics
• Market leading imaging technology
• Adaptive trial capabilities
Innovation for Impact
Our innovation focuses on the
factors that are critical to our
customers in Clinical Development
• Increasing Quality • Reducing Time to Market • Cost Efficiency
Patient Centric Monitoring - ICON’s risk-based, patient-focused methodology for the design and execution of an adaptive monitoring strategy leveraging ICONIK analysis in delivering results that matter in clinical development…
The Impact of Patient Centric Monitoring
ICONIK facilitates targeted usage of monitoring resources with significant reductions in overall monitoring costs
The Impact of Firecrest
Firecrest - An innovative suite of online training, performance support and study management tools that deliver real results at Investigator sites.
Award Winning Multimedia
Improves the effectiveness of Investigator sites
Experience
21
Therapeutic Overview
Study Experience
ICON Efficiencies Increase R&D Productivity
24
While maintaining Quality
ICON Reduces Cost
Cumulative Savings
Time
Cost Savings
Decreasing budget variance
Procurement efficiencies
Reducing COs &protocol amendments
RBM
Which Increases R&D Productivity
Cost/Study & Time/Study decrease
Time
R&D budget buys more Studies
Study Duration
Over time, study duration decreases
SSU
LPR
DBL
Contracting
Time
ICON Accelerates Trials
Market Relevant Expertise
Continued enhancement of TA Expertise
Targeted M&A in areas of customer need
9%
24%
39%
13%
15%
PHD or HigherMasters DegreeBachelor degreeDiploma/CertificateOther
ICON Plc – Staff Educational Qualification
